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SUMMARY
Functional Gastrointestinal Disorders (FGIDs) are chronic
ailments that interest million of subjects on a daily basis.
FGIDs are characterized by recurrent symptoms that
indicate a dysfunctional GI tract despite that an organic etio-
pathogenesis cannot be identified on diagnostic studies.
Although the precise etiology of these disorders remains
unknown, there is a growing body of evidence to support gene-
tic, infectious, psychosocial and neurologic factors which contri-
bute to the developing of these pathologies.
Family studies provide strong evidence for a clustering
of FGIDs in families and this point towards the role of some
hereditary factors and polymorphism of adrenergic, opioidergic
and serotonergic receptors as well as G-protein-beta3 and sero-
tonin receptors are suitable mechanisms.
Acute GI infection and mucosal inflammation appear trig-
ger a cascade of events that ultimately results in the manifesta-
tion of FGIDs, and is reasonable to assume that functionally rele-
vant polymorphisms of genes with immunomodulating and neu-
romodulating features might play a role.
The disturbed central processing of abnormal sensory
afferent signals and visceral hypersensitivity play a major role,
while stress and psychiatric disturbs could have a remarkable
comorbidity role, but they cannot be the only cause of symp-
toms. FGIDs have been relegated to the “prison” of the psycho-
somatic diseases and identified exclusively by symptoms.
A growing body of evidence seems demonstrate that
FGIDs could be organic, multifactorial diseases and that the
nervous system and its components play a fundamental role in
their pathophysiology. 
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RIASSUNTO
I Disturbi Funzionali Gastrointestinali (DFGI) sono patolo-
gie croniche che coinvolgono quotidianamente milioni di persone.
Essi sono caratterizzati dalla ricorrenza dei sintomi,
indice di una alterata funzionalità del tratto gastrointestinale
anche se non ne è ancora nota una etiologia organica.
A tutt’oggi non è ancora conosciuta una precisa eziologia
di questi disturbi tuttavia è sempre più evidente il ruolo svolto da
fattori genetici, infettivi, psicosociali e neurologici. 
Studi su gruppi familiari, hanno identificato un cluste-
ring per le malattie funzionale dell’apparato digerente, per le
quali sono importanti sia i fattori ereditari che il polimorfismo
di recettori adrenergici, oppioidi e serotoninergici.
Si ritiene che infezioni acute del tratto gastrointestinale e
la flogosi della mucosa possano essere fattori scatenanti di una
cascata di eventi che determinano le manifestazioni cliniche
dei DFGI per i quali potrebbe svolgere un ruolo fondamentale
il polimorfismo di geni immunomodulanti e neuromodulanti.
L’anormale riconoscimento di segnali sensitivi afferenti
e l’ipersensibilità viscerale potrebbero essere fattori determi-
nanti per i DFGI, mentre lo stress ed i disturbi psichiatrici
anche se possono avere un importante ruolo nella comorbidità,
non possono essere l’unica causa dei sintomi. Attualmente i
DFGI sono classificati come una patologia psicosomatica e
come tale identificata esclusivamente dai sintomi.
Tuttavia crescenti evidenze scientifiche sembrano dimo-
strare che i DFGI potrebbero essere delle patologie organiche,
multifattoriali nelle quali il sistema nervoso e le sue differenti
componenti potrebbero svolgere un ruolo fisiopatologico fon-
damentale.
Parole chiave: Disturbi Funzionali Gastrointestinali (DFGI),
Sistema Nervoso Centrale (SNC), Sistema Nervoso Enterico
(SNE), Genetica, Infezioni Gastrointestinali, Infiammazione,
Neuroimmunomodulazione
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Introduction
Despite a worldwide and continuous increa-
sing interest in Functional Gastrointestinal
Disorders (FGIDs) by researchers, clinicians as
well pharmaceutical industry, the precise etiology
of these disorders remain substantially unknown.
On the other hand, it is very important to focus on
FGIDs because they are chronic disorders that
result in a great deal of disability and in a signifi-
cant burden for patients, physicians, healthcare pro-
viders and employers.
Epidemiologic data on FGIDs report that they
are characterized by recurrent symptoms (i.e. heart-
burn, abdominal pain or discomfort, bloating, nau-
sea, vomiting, early satiety, constipation or
diarrhea) that indicate one or more dysfunctions in
the GI tract despite that an organic reason for the
symptom generation could not be demonstrated by
diagnostic studies.
It is reputed that about 40% of all gastroente-
rology clinic visits are for FGIDs(1) and a more
recent survey of generalists and gastroenterologists
demonstrated that nearly one third of their patient’s
population had symptoms referred to Irritable
Bowel Syndrome (IBS).
Characteristically, many patients with FGIDs
have overlapping symptoms like dyspepsia, pain,
IBS symptoms, heartburn or bloating, suggesting
common pathophysiologic mechanisms.
However, the symptoms are typically chronic
in nature, but they wax and wane, are worsened by
meals and are often induced or aggravated by psy-
chosocial stressors or by total life event stress. 
Symptoms of FGIDs can vary over time and a
subset of people appear to cycle in and out of
symptoms, probably depending on changing of
environmental exposure and psychological distress,
and on central or peripheral neuroplasticity. 
The complexity of neural mechanisms invol-
ved in regulating and organizing gut functions is
reflected in very articulated and complex sympto-
matology associated with multifactorial disorders. 
As neurobiology and neurophysiology will
continue to provide new mechanistic insights, there
is a need for improved diagnostic tools in clinical
neurogastroenterology in order to advance our
knowledge on pathogenesis and to realize rationally
targeted therapy.
This article reviews some qualifying aspects
of etiology and pathophysiology of FGIDs in the
light of most interesting and newest observations
concerning the connections and interactions
between the different parts of nervous system, the
gut, the inflammation and related neuroimmune
response, psychological factors, motility and visce-
ral hypersensitivity. 
Putative aetiologic and pathophysiologic factors
Traditionally FGIDs have been considered as
disorders typified by disturbed gastrointestinal
motility, visceral hypersensitivity and psychosocial
factors leading to various and often coexisting
symptoms. Our understanding about the connec-
tions existing between the different pathophysiolo-
gical alterations and various symptoms referred by
patients is very lacking.
In the last years many studies  have provided
clear evidence that in FGIDs an altered interplay
exists between the different parts of the nervous
system along the so-called “brain-gut axis”.
Besides, immunological changes, post-infec-
tion low grade inflammation, abnormal levels of GI
neuropeptides and hormones, as well as genetic fac-
tors might play a fundamental role in the genesis of
FGIDs. The researchers and clinicians turn their
effort to understanding how classical pathophysio-
logical factors, such visceral hypersensitivity, alte-
red motility and psychosocial factors could be cor-
relate and integrate with the most recent scientific
findings and progresses.
Genetics
Observational and clinical studies seem to
suggest a genetic contribution to the development
of FGIDs, because they run more frequently in
families where the parents suffer for dyspepsia, IBS
or heartburn. Twin studies demonstrated concordan-
ce rates for FGIDs of 33% for monozygotic twins
and 13% for dizygotic twins(2), but the concordance
rate was higher between mother and child when
compared with monozygotic twins suggesting a
social learning effect on the development of IBS(3).
Other researchers(4) observed that the presence
of dyspepsia and IBS in a patient was significantly
associated with reporting of the same symptoms in
first-degree relatives, suggesting a familial link.
A recent study found that the polymorphisms
in the promoter region of the serotonin reuptake
transporter gene are significantly associated with
IBS with diarrhea(5). Moreover, in a case-control
study was observed that individuals homozygous
for a G protein beta-3 subunit gene polymorphism
were more likely to have unexplained upper abdo-
minal symptoms and FGIDs(6) and various prelimi-
nary findings also suggest that FGIDs may be asso-
ciated with other selected gene polymorphism,
including those in IL-10, alpha adrenoceptor, and
serotonin reuptake transport (SERT)(7,8,9).
It is unlikely that a single genetic factor causes
FGIDs, it is rather more likely that a genetic fac-
tor/s modulates the risk of developing the abnorma-
lities that are characteristic of FGIDs after exposure
to one or more environmental factors.
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Genes of serotonergic system
Serotonin (5-hydroxytriptamine, or 5-HT)
modulates sensory and motor function in the
gastrointestinal tract. Seven classes of 5-HT recep-
tors have been identified on the basis of differences
in structure, molecular action and function and in
particular the 5-HT type 3 receptor is involved in
mediation of postprandial colonic motor function.
In IBS patients stimulation of 5-HT type 3
receptors induces cramps, urgency, diarrhea and
high-amplitude, peristaltic, colonic contractions(10).
Individuals who are homozygous or heterozy-
gous for the 5-HT-transporter-gene-linked poly-
morphic region (5-HTTLPR) deletion, have reduced
transcription of serotonin reuptake transporter gene
SLC6A4, reduced expression of its product (the
sodium dependent serotonin transporter) and redu-
ced reuptake of serotonin(11). In patients with diarrhea
predominant IBS, genotyping for the 5-HTTLPR
polymorphism demonstrated an association between
polymorphism and colonic transit time.
Interaction of adrenergic and serotonergic
receptors
An interaction between serotonin and norepi-
nephrine in the modulation of gastrointestinal func-
tion is evident and an association has been observed
between functionally distinct genetic polymorphism
in SLC6A4 or genes that encode α2A and α2C adreno-
ceptors and specific IBS subtype(9). The AA. sugge-
sted that a del322-325 polymorphism in ADRA2C,
gene that encodes the α2C adrenoceptor, is associated
with an increased likelihood of constipation in
patients with functional disorders of the lower inte-
stinal tract and with an increased likelihood of a high
frequency and severity of somatic symptoms.
Various combinations of polymorphysms in
the genes that encode the α2A adrenoceptor and α2C
adrenoceptor, or of the del322-325 polymorphism
in ADRA2C and polymorphisms in SLC6A4, have
evidenced a high somatic symptom score(9).
Cholecystokinin
This neuropeptide is released within the duo-
denal and jejunal mucosa in correlation with the
presence of various nutrients like protein and fats.
Cholecystokinin provokes pancreatic enzyme
secretion, inhibition of gastric empting and contrac-
tion of gallbladder.
The actions of cholecystokinin are mediated
via two receptors, the CCK-A and CCK-B which
are located in the peripheral and central nervous
system(12). At the gastrointestinal level the effects of
cholecystokinin are mediated via the receptors
CCK-A located in the smooth muscles and in the
vagal afferent nerves of the GI tract.
Blockade of CCK-A receptors could be a new
approach to stimulate gut motility and to reduce
colonic transit time in patients with constipation-
predominant IBS. Variations in the genes encoding
the cholecystokinin receptors, could change the
response to endogenous cholecystokinin.
Genotypes studies in patients with constipa-
tion-predominant IBS have revealed that a poly-
morphism in the CCKAR gene could be functional-
ly significative, because the 779C variant is asso-
ciated with slower gastric emptying.
Cytokines
Chaudhary and Truelove(13) first suggested that
an infection could lead to the development of IBS.
Both retrospective and prospective studies
have shown that approximately 10%-30% of indivi-
duals with acute gastroenteritis later develop symp-
toms of IBS(14, 16). Subsequent data have firmly esta-
blished that gastroenteritis have a significant role in
the genesis of IBS(17,18) and a recent study confirmed
that in patients with bacillary dysentery (due to
Shigella species), IBS develops significantly more
frequently than in controls(19).
Although the definition of IBS states that no
active inflammation is present to cause symptoms,
recent studies demonstrated that an increased number
of mast cells is present in the terminal ileum of
patients with IBS, and that patients whose ulcerative
colitis is in remission, report IBS-like symptoms (20).
Moreover, the number of T lymphocites and
enteroendocrine cells is persistently elevated in
patients with postinfectious IBS. The above mentio-
ned data suggest that in these patients there is a
continuing inflammatory stimulus with increased
gut permeability(17). Cytokines are involved in the
regulation of the immune and inflammatory respon-
ses. We know proinflammatory cytokines such as
tumor necrosis factor (TNF) and interferon γ, and
anti-inflammatory cytokines such as interleukin 10
(IL 10) and transforming growth factor β1. Study of
polymorphisms in the genes that encodes these
cytokines has revealed the presence of alleles asso-
ciated with high or low cytokines production(21).
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There is a strong association between IL10
genotypes and IBS.
The low prevalence of the high-producer
genotype in patients with IBS suggest that indivi-
duals that produce low amounts of IL10 could be
more prone to develop IBS(22).
SERT expression and genetic factors
Enteric nervous system (ENS) represents the
most vast and complex component of peripheral
nervous system. The most important functions in
the ENS are carried on by 5-HT. The most impor-
tant source of Serotonin (5-HT) is principally loca-
ted in the human bowel, primarily in the enteroch-
romaffin cells (EC). 5-Ht is released from EC cells
in response to luminal stimuli.
Once released, serotonin acts on receptors loca-
ted on the processes of sensory neurons that pass into
the lamina propria. These include branches of intrin-
sic sensory neurons whose cell bodies are in submu-
cosal and myenteric ganglia, sensory neurons in spi-
nal (dorsal root) ganglia and vagal (nodose) ganglia.
When serotonin is released from EC cells pro-
vokes activation of vasodilatory, secretory and
motor reflexes, as well as stimulation of afferent
signals to the spinal cord and brain.
The nerve terminals that release serotonin,
express a serotonin selective reuptake transporter
(SERT), very effective in terminating the signals
that they initiated. Intestinal mucosa has an enor-
mous capacity to remove the 5-HT from the inter-
stitial space because all the cells in the luminal sur-
face of the gut express SERT. In the postprandial
phase, serotonin enters the bloodstream, where it is
removed by platelets which also expresses SERT.
The expression of SERT seems to be influen-
ced in relation to the individual genetic makeup(23)
and the activation of G-protein-coupled receptors
can provoke changes in SERT by modulating its
transcription by moving the transporter to or away
from the plasma membrane, so genetic factors
might modify SERT expression and function in the
intestinal epithelium(24). The variability in SERT
expression depends on SERT gene-linked poly-
morphic region (SERT-LPR)(25).
However, not all studies demonstrated a corre-
lation between SERT-LPR alleles and SERT
expression. Moreover, analysis of mRNA levels fai-
led to detect a correlation with SERT-LPR geno-
type(26), between SERT-LPR alleles and promoter
activity(27); no significant correlation was observed
between SERT-LPR and binding of SERT ligands
in the brain of healthy volunteers(28).
The relation between SERT-LPR and FGIDs, in
particular IBS, is not firmly defined, because the stu-
dies on this topic are somewhat contradictory(5, 29-32).
In general these studies demonstrated a link
between SERT-LPR and specific subtype of IBS,
but not in IBS as a whole, suggesting the idea that an
universal etiology for IBS does not exist. To date is
not possible to draw a definitive conclusion about the
genetic predisposition to develop IBS, but the above
preliminary data seem to be promising. Observation
that functional dyspepsia (FD) runs in families sug-
gest a genetic basis to the development of this disea-
se(4). A case-control study showed that individuals
homozygous for a G protein beta-3 subunit gene
polymorphism were more prone to have unexplained
upper abdominal symptoms and FD(6).
In conclusion the previous mentioned studies
do not establish firmly causality and the data are limi-
ted in number. Positive association between genetic
variants and disease have to be considered with cau-
tion because false-positive results are frequent.
The complex interaction of genes, environment
and phenotype will continue to present challenge to
researchers. It is likely that future studies will
demonstrate that genetics play a significant role in
the etiology and pathogenesis of FGIDs, providing
an explanation and theoretical framework for the
heterogeneity of these clinical manifestations.
Infection and neuro-immune interactions
The enteric nervous system and immune system
are most effective defenders of the body’s enteric
function. Hypersecretion and motility (accelerated
transit) represent the preferred ways to defend the
organism. The enteric and immune systems are stric-
tly integrated and receptors for enteric neurotran-
smitters are located on the Peyer’s patches and
lymphocites are located in the lamina propria.
Motor and secretory response are sensitized to
specific antigens (e.g. food, bacterial toxins, parasi-
tes and chemical agents) and intestinal inflamma-
tion provokes active and integrated gut motility and
enteric nervous system reaction. Strict connections
exist between the submucosal plexus and myenteric
plexus which cohordinate mucosal secretion with
propulsive motor behavior in the states of flogosis.
For example, during the enteritis caused by
Clostridium difficile toxin A, enteric neurons are
excited and sympathetic transmission is blocked.
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The immune system and its messengers, the
inflammation mediators, sensitise the primary affe-
rents fibres and in particular the C fibre nociceptors,
which induce a secondary spinal activation.
This is the so-called “neurogenic inflamma-
tion”. The messengers of inflammation are calcito-
nin gene-related peptide, tackykinins, 5-HT, hista-
mine, prostaglandins, leucotrienes, cytokines and
mast cells which are directly innerved by projec-
tions from the central nervous system and degranu-
late with the release of many substances like 5-HT,
histamine and nerve growth factor. Newer classes
of receptors involved in neurogenic inflammation
are evolving, for example the cell-surface protease-
activated receptors 2, which seems to be related to
inflammation, but also to hyperalgesia.
Neurogenic inflammation is reduced by some
of the receptor antagonists which compete with the
released inflammatory mediators (e.g. neurokinin
receptor antagonists). The pathophysiology of IBS
is partially understood, but there are various evi-
dence to support both host and environmental fac-
tors. The role of enteric infection in the pathogene-
sis of IBS has been recognized and several studies
have evaluated the risk factors for its onset. In par-
ticular two recent meta-analysis(33, 34) demonstrated
an increase of post-infective IBS (PI-IBS) in
subjects who suffered of acute gastroenteritis.
In particular, Thabane & Coll (34), observed a
strong association between intestinal infection and
IBS with an estimated incidence of 10%. The deve-
lopment of symptoms consistent with IBS and their
meta-analysis suggested that the odds of developing
IBS are increased about sixfold after acute gastroin-
testinal infection. The AA. confirmed an association
between increasing risk of PI- IBS and younger age
and in some way this difference is explained. by the
age-gender effect, considered that many functional
disorders are more common among females and
could be both referred to circulating female hormo-
nes and to psychological distress frequent among
young women. A recent study(35) outlined that beha-
vioral and cognitive profiles and emotion are signi-
ficant risk factors for the development of PI-IBS,
suggesting an interactive model of psychology and
biology, considered that infections may trigger
symptoms and psychologic factors may maintain
and prolong them over time.
In general, seems that more severe are gastroin-
testinal infection (bacterial infection, prolonged
fever, diarrhea, vomiting), more increased will be the
risk of PI-IBS(33, 36).
In the literature are present more limited data
on the possible correlation between functional
dyspepsia (FD) and infectious illnesses.
Tack(37) described a group of patients with
dyspeptic symptoms after prior gastrointestinal
infectious disease. 
A larger proportion of patients with post infec-
tious dyspepsia had complaints of nausea, vomi-
ting, early satiety and weight loss.
The patients manifested an impaired accom-
modation of the proximal stomach and sumatriptan,
an activator of nitrergic neurons, did not cause fun-
dic relaxation in the patients with post infectious
dyspepsia. This observation indicates a dysfunction
at the level of gastric nitrergic neurons in these
patients, leading to impaired accommodation.
Several, well-controlled studies did not
demonstrated significant relationship between FD
and Helicobacter pylori infection. Sarnelli et al.(38)
demonstrated that H pylori infection was not asso-
ciated with FD with respect to symptoms, rates of
gastric empting, degree of gastric relaxation, or sen-
sitivity to gastric distension. Many other studies fai-
led to demonstrate a symptomatic benefit in
patients eradicated(39, 40), but a recent Cochrane data-
base meta-analysis concluded that eradication of H
pylori led to a small but significant improvement of
dyspeptic symptoms(41).
There is a sufficient evidence that prior infec-
tious disease may predispose the patient to develop
FGIDs and that exposure to a viral or bacterial
infection inducing an inflammation, could provoke
an alteration in function of enteric nervous system.
Inflammation is very useful for survival but also
can induce considerable morbidity and mortality. 
The inflammation has profound effects on
neuronal function and inflammatory neuropathy is
becoming an important issue in neurogastroentero-
logy(42). Inflammation of enteric ganglia in different
tracts of gastrointestinal tube by the infiltration of
inflammatory cells produces dysfunction and dege-
neration which over time can lead to aganglionosis
and severe motor disturbances. Another important
role is played by glia cells which are much more
frequent of neurons (4:1) and have a fundamental
role in protecting the integrity of the gut.
Enteric glia are strictly associated with neu-
rons in the enteric nervous system (ENS) and
display morphologic and molecular similarities to
the central nervous system (CNS) astrocytes,
because like them are actively participants in neuro-
nal communication by neurotransmitter receptors.
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In the ENS the purine adenosine triphosphate
(ATP) is co-released with the neurotransmitter
acetylcholine and noradrenaline. Enteric glia express
purinergic receptors and respond to ATP in vitro sug-
gesting that enteric glia actively participate in func-
tional gastrointestinal response to nerve signaling.
Gulbransen and Sharkey(43) very recently
demonstrated that exists a functional purinergic
neuron-glia communication in the enteric neuron
system, suggesting the possibility that ATP released
with neurotransmitters during enteric synaptic tran-
smission functions as a signal to enteric glia.
Aube et al.(44) used a transgenic approach to
disrupt glia in order to examine changes in the phe-
notype of enteric neurons and functional conse-
quences for intestinal motility and permeability.
The study showed that glia disruption induces
changes in the neurochemistry of enteric neurons
leading to altered motility and increased epithelial
permeability as a consequence respectively of
decreased of vasoactive intestinal peptide (VIP) and
substance P expression  in submucosal plexus and a
decreased nitric oxide synthesis with concomitant
increase of choline acetyltransferase expression in
the myenteric plexus(44). Inflammation activates
enteric glia cells and they play a role in antigen pre-
sentation and cytokine production and in presence
of IL-1b, TFN-α, lipopolysaccaride and proinflam-
matory cytokines, their number is increased(45).
Anti-inflammatory citokines are useful in con-
trolling the intensity of inflammation, but when
pro-inflammatory cytokines are unchecked they can
produce dramatic consequences. These studies sug-
gest that the alterations in glia functions impair the
gastrointestinal mucosal barrier system and in con-
cert with enteric nerves may be involved also in
cancer and inflammatory bowel disease (IBD)(46).
Vagus nerve plays an interesting role in anti-
inflammatory mechanisms. In fact, acetylcholine
released within the gut wall, following vagal stimula-
tion, block nicotine receptors on resident macrophage
to inhibit their production and release of pro-inflam-
matory TNF-α. The intriguing question is: what links
the vagus and macrophage in the gut wall? De Jonge
et al.(47) demonstrated that cholinergic neurons come
into close proximity with macrophages in the rat
ileum. These neurons could be vagal efferent fibres,
but probably  are of enteric neural origin(48).
De Jonge(47) suggests that surgical manipulation
provokes macrophage activation and recruitment that
lead to the release of proinflammatory cytokines.
Specifically, vagal stimulation suppress the inflam-
matory response via a Jack2 STAT3 signaling
pathway with an action of phosphorilated STAT3 on
its DNA response elements. The nicotinic receptor
mediating the immune-suppressive effect, was the
α7 subtype, distinct from the α3β4 subtype that typi-
fies ganglionic transmission in the ENS.
This could point to a direct action of pre-gan-
glionic vagal efferents on macrophage function or a
neuro-effector response of acetylcholine from post-
ganglionic neurons that is not mediated by muscari-
nic receptors(47).
Carbon monoxide is produced in neurons by
heme oxidase 2 (HO2). This enzyme is localized in
a sub-population of neurons that also produce NOS
and its reduction induces a deficit in neuromuscular
transmission and gut transit is slowed.
During tissue injury, like it happens during
abdominal surgery, carbon monoxide is produced
by another enzyme, heme oxidase 1 (HO1).
The role of carbon monoxide in gastrointestinal
tract has been recently reviewed(49). Nitric oxide (NOS)
and carbon monoxide are gaseous mediators found
both in the brain and in the gastrointestinal tract.
NOS is present in enteric neurons but it is also
generated by components of the gastrointestinal
immune system, in particular macrophages and
monocytes, as a consequence of intestinal manipula-
tion and this mechanism play an important role in
post-surgical smooth-muscle dysfunction tipical of
ileus. L-NMMA, an NOS inhibitor, provokes an
immediate post-surgical recovery of gastrointestinal
motility, inducing the authors to think that NOS is
the final common pathway for postoperative inhibi-
tion of motility(50).
Hydrogen sulphide (HS) has been recently sug-
gested as the third gaseous mediator(51). It is a vasodi-
lator and it is present in CNS(52). It is synthesized in
neurons and it has an excitatory neuromodulator
action in the enteric nervous system(53).
The source of HS could be enteric neurons,
intestinal microflora and diet. Red meat, high protein
intake and alcohol are associated with relapse in
ulcerative colitis as a consequence of high luminal
concentration of HS which could compromise use of
the endogenously producted butyrate, a short-chain
fatty acid that has been shown to contrast some ulce-
rative colitis pathologies.
The positive effect of probiotics on treatment of
inflammatory conditions, including IBS, might be
related to prevention of negative effects of HS.
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Mast Cells
Mast cells act as a modulatory interface
between neurons and their environment and this
interaction is bidirectional. A local triggering cause
induces peripheral release of substance P (SP) pre-
sent within extrinsic sensory nerve terminals throu-
gh an axon reflex. The SP acts on its receptors loca-
ted on epithelial, inflammatory, neuronal and/or
smooth muscle cells, principally during inflamma-
tion when NK1 receptors are much more present(54). 
NK receptors are also located on mast cells
and the exocytosis of their granule contents stimu-
late nerve endings, maintaining an inflammatory
condition. The mast cells mediators include various
pro-inflammatory substances (tryptase, histamine,
platelet activating factor, prostaglandins, cytokines
and leukotriens) which can stimulate residential
macrophages on the one hand and intrinsic and
extrinsic afferent neurons on the other hand(55).
There is an accumulating evidence that symp-
toms in a group of IBS patients are correlated to
post-infectious sub-clinical inflammatory altera-
tions in the gut wall and intestinal dysbiosis exists
in at least a subset of patients, more probably like a
subtle alteration than a gross bacterial overgrowth(56)
determining an altered immune nerve signaling.
Various authors have observed a strong
morphological association between mast cells and
nervous fibers in biopsies taken from IBS
patients(57). This association has found a functional
correlation in the observation that various media-
tors released from human intestinal mast cells sti-
mulated with IgE, causes direct activation of gui-
nea-pig and human enteric neurons(58). This cocktail
of various mediators led to an exaggerated neuro-
immune signaling in IBS patients.
Recently, has been described that patients with
IBS showed an abnormal IL-10/IL-12 ratio, sugge-
stive for a pro-inflammatory condition(59).
The alleviation of symptoms and the normali-
zation of the ratio of pro-inflammatory and anti-
inflammatory cytokines was obtained with the
administration of the probiotic microorganism
Bifidobacterium infantis 35624. Likewise, symp-
toms in IBS patients were relieved with administra-
tion of the probiotic combination VSL3(60).
Beyond the immune modulatory action of pro-
biotics it has been shown that the ENS might be
another target, based on the finding that food sup-
plementation with the probiotic yeast Saccharo-
myces boulardii alters the neurochemical phenotype
of pig myenteric neurons evidenced by a decrease
of calbindin expression, while other neuronal popu-
lations are not affected(61). The probiotic-evoked
change in phenotype seems to have some functional
implications(62).
The authors found in mice that a perturbation
of the gut microflora is associated with an increase
of substance P-immunoreactivity and visceral
hypersensitivity, while the administration of
Lactobacillus paracasei normalized substance P-
immunoreactivity and hypersensitivity. 
In conclusion, the interactions between ENS
and immune systems remains a very important
topic and very interesting progresses has been
achieved to shed light on the neuro-immune axis in
the human gut, but there is still much that we do not
know.
Serotonin as signaling molecule
Normal GI function relies on properly functio-
ning brain-gut axis, which involves the coordinated
interplay of the GI musculature, the CNS, the auto-
nomic nervous system (ANS), and the enteric ner-
vous system (ENS). Impaired function or coordina-
tion of any of these systems, or the communication
between these system and the GI musculature, can
lead to symptoms of dysmotility and altered sen-
sory perception, which are characteristic of IBS and
other GI motility disorders(63). The neurotransmitter
serotonin (5-hydroxytryptamine -5-HT) is a predo-
minant signaling molecule in the ENS and the most
part of serotonin (95%) is found in the gut(64).
Serotonin facilitates communication between
muscles, secretory endothelium, endocrine cells,
and the vasculature of the GI tract, playing a key
role in normal GI tract functioning(65). In addition,
serotonin plays an important role in the communi-
cation between ENS and CNS.
Enterochromaffin cells (EC cells) are located
within the mucosa of gastrointestinal wall and they
synthesize and store serotonin. 5-HT is synthesized
too by serotonergic neurons of myenteric plexus.
EC cells contain one form of rate-limiting
enzyme in serotonin’s biosynthesis, tryptophan
hydroxilase-1(TpH-1), and enteric and central sero-
tonergic neurons contain TpH-2, which is a diffe-
rent gene product. When the mucosa is stimulated
by the material passing through the gastrointestinal
lumen, serotonin is released by EC cells and it
binds to its receptors (primarily 5-HT1P receptors)
on intrinsic primary afferent neurons whose cell
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bodies are located in submucosal and myenteric
ganglia, as well as sensory neurons located in spinal
(dorsal root) ganglia and vagal (nodose) ganglia,
initiating secretion, peristalsis and vasodilatory
reflexes, as well as stimulation of afferent signals to
the brain and spinal cord. Serotonin also binds to 5-
HT4 receptors on interneurons, which increase the
transmission of the signals to motor neurons, resul-
ting in augmented peristaltic activity.
Serotonin mediates the signaling between the
ENS and the CNS and so modulates pain perception
by binding to 5-HT3 receptors present on efferent
sensory innervations coming from the vagus and the
spinal nerves. We said that the serotonin signaling
process is regulated by the SERT molecules which
are produced by intestinal epithelial cells(66).
Human studies demonstrated that defects in
serotonin signaling contribute to the physiology of
IBS and other functional GI disorders. In patients
with IBS intestinal biopsies have shown a signifi-
cantly lower mucosal serotonin concentrations pro-
bably as a consequence of lower mRNA levels of
tryptophan hydroxilase, which is the rate-limiting
enzyme in serotonine synthesis(67).
In another study(68), was observed that in the
biopsies of patients with IBS constipation variant
(IBS-C) the levels of serotonin were higher than in
patients with the IBS-D variant or in healthy con-
trols. Increased understanding of the role of seroto-
nin in gut physiology has determined the develop-
ment of drugs designed to modulate its function in
the GI tract. The use of serotonergic agents, in par-
ticular Alosetron (5-HT3 receptor antagonist) in
women with IBS-D and Tegaserod (5-HT-4 recep-
tor agonist) in the short-term treatment of patients
younger than 65 years of age with chronic constipa-
tion, has provided contrasting results.
Actually the new prescribing label of
Alosetron, approved by the US Food and Drug
Administration (February 2005), includes a “black
box” warning regarding: a) restricted indication for
women with severe IBS-D who have not responded
to conventional therapy and in whom anatomic and
biochemical abnormalities have been excluded; b)
the risk for serious GI adverse events, such as
ischemic colitis; c) a new starting dosage; d) a
requirement that physicians and patients subscribe
to a risk-management program.
It is evident that serotonin signaling is altered
in IBS-D, IBS-C and PI-IBS, but the cause and
effect relationship of epigenetic changes in the ele-
ments of 5-HT signaling is unclear, because we do
not know if changes in 5-HT signaling contribute to
the modifications in GI function and sensation typi-
cal of IBS or vice versa elements of 5-HT are alte-
red in response to an altered function and sensation.
In other words we do not know whether 5-HT signa-
ling changes in response to altered gut function or
altered 5-HT signaling, can lead to changes in gut
motilty. In fact, administration of low concentrations
of SSRI fluoxetine (Prozac), increase the rate of pro-
pulsive motility at low concentrations, while slow
motility at higher concentrations(69, 70).
In general, receptors which have been identi-
fied for 5-HT are: 5-HT1A-E,P, 5-HT2A,B,C , 5-
HT3, 5-HT4, 5-HT5, 5-HT6, 5-HT7, in prevalence
localized in the gut (5-HT1A, 5-HT1P, 5-
HT2A,B,C, 5-HT3, 5-HT4, 5-HT7)(71).
5-HT3 and 5-HT4 receptors have proven to be
possible targets for the treatment of diarrhea-predo-
minant and constipation-predominant IBS, but they
are not responsible for all the effects of 5-HT in the
GI tract and other 5-HT receptor subtypes contribu-
te to the pathophysiology of IBS. Alosetron and
Tegaserod might be acting through antagonism of
5-HT2B receptors. Both compounds inhibit the
excitatory effects of receptors in the human colon.
Thus it is possible that the effects could be due to
blockade of 5-HT2B rather than to the activity at
either  5-HT3 and 5-HT4 receptors. 5-HT7 receptor
subtypes may also be promising targets for the futu-
re which are expressed in both the small and large
human intestines(72). Tonini et al.(73). observed that 5-
HT7 receptors may modulate the nitric-oxide
mediated intestinal accommodation and smooth
muscle relaxation in guinea pig ileum.
Endogenous 5-HT was involved in smooth
muscle accommodation in the preparatory phase of
peristalsis by direct activation of 5-HT7 receptors. 
Moreover, the authors suggest that abnormal
stimulation of the 5-HT7 receptor may contribute to
some clinical syndromes like IBS and that it could
be a novel target to treat diarrhea-predominant
IBS(73). Functional 5-HT7 receptors are present in
human microglial MC3 cells, suggesting that they
are involved in neuroinflammatory processes(74).
It is possible imagine that 5-HT7 may be one
of the supposed links between changes in serotonin
signaling and metabolism on one hand and the
symptoms experienced by post-infectious IBS
patients on the other hand.
The 5-HT1P receptor seems to mediate a
response that is different from that of any currently
cloned 5-HT receptor.
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The lack of molecular identity has inhibited
the research on this target. Gershon and coll. publi-
shed a series of abstracts to suggest that this recep-
tor is in fact a heterodimer of the 5-HT1B/D and
D2 dopamine receptor. The 5-HT2B are localized in
both smooth muscle and nerves, and their activation
can cause direct smooth muscle contraction in the
human ileum and can enhance cholinergic-neuron
mediated contractions in human colon(75). The locali-
zation and the enhancement of 5-HT2B receptors,
suggest that blockade of 5-HT2B receptors might
reduce prokinesis.
In conclusion the role of 5-HT in neurologic
physiology of gastrointestinal tract is indubitable
and clear evidence exists for a role of disturbed
mucosal 5-HT signaling in IBS, as well as in other
FGIDs. It is clear that the sequence of events that
induces the serotonin signaling can be modified and
transformed in response to different physiological
and pathophysiological conditions. It is very proba-
ble that altered 5-HT signaling collaborates to indu-
ce an abnormal gut function and to heighten the
sensitivity in IBS patients.
Psychosocial factors and Central dysregulation
Psychosocial factors seem to be important in
FGIDs although whether these factors directly alter
gastrointestinal function is not clear(76-78).
In fact, it is possible that psychosocial factors
may be involved in the ethiopathogenesis of
FGIDs, not just influencing the frequence and seve-
rity of symptoms and health care seeking of the
patients. In other words, are psychosocial factors
just a consequence of symptom severity or are stric-
tly related to FGIDs “per se”? Two population-
based studies observed that IBS and psychosocial
factors were associated and this association was
present also in subjects who had not sought health
care for their symptoms(79, 80).
Physical and sexual abuse are conditions fre-
quently reported by women or children and psycho-
social factors are mediating factors linking abuse
with the development of fun-ctional gastrointestinal
symptoms(81, 82). Interestingly, the association between
self-reported abuse and the impaired functioning in
patients with severe IBS seems to be mediated by a
general tendency to report various bodily symp-
toms(83). Cognitive factors are considered important
for IBS and other functional disorders. Patients with
severe depression report more severe abdominal
pain, whether for a particular tendency to cata-
strophic thinking, but also for interpersonal problems
in a complex way.
For both Functional Dyspepsia (FD) and IBS,
it clearly appears that severe chronic life stress
threat together with the prolonged coping associa-
ted with the stressor, have significant effects on
symptoms onset and relapsing over time(84). It is
interesting that psychological stress and other
cognitive aspects can also be related to sensorimo-
tor dysfunction in FGIDs patients(85).
For example, in IBS the severity of psychosocial
disturbance parallels the degree of small bowel motor
or sensory dysfunction(86), whereas exposure to psy-
chological stress provokes rectal hypersensitivity(87).
Hypervigilance is another factor that influen-
ces symptom reporting by IBS patients during rec-
tal distension test(88). In FD cognitive factors influen-
ce both symptom induction and sensorimotor
dysfunction(89, 90). Chronic stress induce in rats an alte-
ration of mucosal defences against luminal aggressi-
ve factors like bacteria. Intestinal permeability is
increased during stress via a cholinergic mechanism
that requires the active presence of mucosal mast
cells. Other mediators of stress-induced gastrointesti-
nal sensorimotor responses are norepinephrine and
corticotrophin releasing factor (CRF). Human data
suggest that IBS patients are sensitive to CRF
effects on colonic motility and infusion of CRF
increases rectal sensitivity(91).
CRF-1 receptor mediates stress-induced increa-
ses in colonic contractility and CRF-2 mediates stress
induced gastric hypomotility and surgical ileus(92, 93).
Brain-gut interactions play a fundamental role in
the regulation of digestive processes, in the modu-
lation of immune system and in the co-ordination in
the gastrointestinal apparatus of the global emotio-
nal and physical state.
Disturbed brain gut-interactions likely provoke
the generation of symptoms of FGIDs., alterations of
immune activity in IBS and various eating disorders.
Positron emission tomography (PET) and
functional magnetic resonance imaging ( fMRI)
permitted the observations of various brain sites
activation in consequence of pain stimulation in
health and IBS. The results reported by different
studies on processing of pain in IBS patients are
often divergent , but, taken together, existing litera-
ture suggests that IBS patients respond to visceral
distension with an increased activity in some sen-
sory areas(94), in subcortical regions associated with
affect, arousal and autonomic response and in corti-
cal areas involved in attention and affect(95).
Are functional GI disorders gastroenterological or neurological disease? 89
It has been demonstrated that male and female
have some differences in relation to activation of
brain regions(96) and the activation patterns differ
between IBS subgroups based on the predominant
bowel habit(97). A very recent rectal distension study
using fMRI, demonstrated that IBS patients with a
history of abuse complained about more pain, grea-
ter MCC/PCC activation, and reduced activity of a
region implicated in pain inhibition and arousal
(sACC)(98). Such studies emphasize the importance
of external stressors, cognitive and emotional bia-
sing as well as peripheral injury in GI pain(99).
Studies on CRH receptor antagonists in FGIDs
demonstrate the strong modulatory role of the HPA
axis in gut sensorimotor function and the possibility
that  derangements of its normal function occur in
patients with FGIDs. In patients with IBS have
been observed autonomic alterations such low basal
cardiac vagal tone and that has particular relevance
to pain sensitivity(100).
Autonomic Nervous System (ANS) Dysfunction
and Hypothalamic-Pituitary-Adrenal axis
The ANS is a fundamental part of the emotio-
nal motor system and represent a bidiretional, body-
brain interface that integrates afferent bodily inputs
and central motor outputs for homeostatic-emotional
processes(101). In particular, CNS communicates with
the gut through the parasympathetic and sympathe-
tic pathways of the ANS  by modulation of the ENS,
as well as via the hypothalamic-pituitary-adrenal
(HPA) axis. Sympathetically mediated mechanisms
are implicated in different chronic pain syndro-
mes(102) and animal and human data indicate a vagal-
ly mediated inhibition of visceral nociceptive sen-
sory inputs(103) and in this way the ANS might modu-
late visceral sensory perception. The exact mechani-
sms by which sympathetic and parasympathetic ner-
vous systems modulate pain is unknown.
The pro-nociceptive action of the sympathetic
nervous system may relate to the release of prosta-
glandins and/or catecholamines from sympathetic
nerve terminals which are in close proximity to the
terminals of damaged primary afferent nerves and
this could result in the direct activation of afferent
fibers that have developed α-adrenergic receptors(104).
Early life events can definitively influence the
development of corticotrophin-releasing hormone
(CRH) systems, which mediate the expression of
behavioural, emotional, autonomic, and endocrine re-
sponse to stress.
In the animal studies, maternal deprivation in
infancy is associated with enhanced neural CRH gene
expression and increased stress reactivity.
These animals, in adulthood, show a greater
activation of the HPA axis, sympatho-adreno medul-
lary systems, central monoaminergic systems and
greater vulnerability for stress induced illnesses.
In patients with Functional Dyspepsia (FD)
has been proposed that abnormal proximal accom-
modation could be caused by a vagal defect(105), but
studies inducing nausea and gastric dysrhythmias,
have proposed the possibility of central neurohu-
moral dysfunction in the pathogenesis of FD(106). 
Various studies have documented autonomic
dysfunction in IBS, but the results seem to be con-
tradictory depending on different experimental
designs and different populations in study.
Also regarding the HPA axis the results are
divergent, because researchers have demonstrated
attenuated(107), normal(108) and augmented reactivity(109)
of the HPA-axis in IBS patients in response to
various stressors, as well as an association with a
proinflammatory cytokine release(109). It remains un-
clear whether the autonomic alterations in the FGIDs
are a primary phenomenon or merely reflect the bidi-
rectional interactions of CNS-ENS dysregulation.
Visceral hypersensivity
In normal conditions gut is not a source of
conscious sensory experiences. Unpleasant sensa-
tions are only felt acutely or perceived as painful
when stimuli exceed those in the physiologic range. 
The typical colic appears when supraphysiolo-
gic distension with spinal mesenteric afferents
occurs, while ischemic pain occurs when blood
flow in the mesenteric district falls below the phy-
siological level. These stimuli are generally acute,
but many patients without organic diseases com-
plain  of chronic abdominal symptoms, especially
pain. It is evident that in certain circumstances it is
possible to feel stimuli that are normally non-
noxius (allodinynia) or increase afferent discharge
to noxius stimuli (hyperalgesia). These nociceptive
hyperalgesic phenomena are all grouped under the
title of visceral hypersensitivity (VH) and are consi-
dered the hallmark of IBS and other FGIDs.
In 1973, Ritchie et al demonstrated that IBS
patient were more sensitive than normal subjects to
balloon distension of the colon(110). Subsequently, into-
lerance to gastric distension was also observed in
patients with functional dyspepsia(111).
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From the data obtained in control subjects indi-
cating that 40 mmHg is the normal tolerance thre-
shold, about 90% of patients with IBS were classified
as suffering from VH, but severe hypersensitivity
(less than 28 mmHg) was found only in one third of
subjects and was highly specific for IBS. When
distension is done with ascending magnitude, subjects
complain of a lo-wer pain threshold than controls, but
if the same volumes are presented in a random order,
all mean thresholds ( IBS patients and controls) are
very similar(112).
This condition is partly attributable to so-cal-
led hypervigilance, or excessive attention to or fear
of painful stimuli from the gut, and partly due to a
true hypersensitivity demonstrating an altered ela-
boration of visceral stimuli. Visceral sensations are
transmitted from the gut via afferent nerves trave-
ling through the spinal cord to the brain., where the
pain characteristics are perceived and elaborated.
The sensitization could happen either within
the dorsal horn of the spinal cord or in the brain.
The excitability of this way is so intense that
pain attributable to visceral distension is seen over
more dermatomes than normal. Functional imaging
in irritable bowel syndrome, utilizing fMRI and PET,
show an increased flow of blood in particular in the
anterior cingulated cortex during colonic stimulation,
but differing patterns of brain activation are characte-
ristic. These differing patterns could reflect increased
afferent input from rectum and/or greater emotional
response based on previous experiences, for example
child abuse. Most part of these studies show that the
brain signal responding to intestinal distension is
greater in patients with IBS than in controls.
This enhanced brain response could depend on
different conditions: 1) could be determined by an
increased signal arriving from the peripheral gut, 2)
could depend on an amplification of a normal
signal during its travel from gut through the spinal
cord, 3) could be an amplification in the brain, 4)
could be induced by some defects in the descending
inhibitory mechanisms(113).
Many data from literature  seem to confirm
that peripheral mechanisms are involved in the tran-
smission of an enhanced signal to the brain ( for
example inflammation in PI-IBS), but all these data
do not give an absolute proof of this concept,
because we have not valid instruments to evaluate
the signal at level of gut or spinal cord and brain-
stem in humans.
In FGIDs the severity of  visceral hypersensiti-
vity does not correlate with the severity of clinical
symptoms and it is possible to conclude that VH is
a heterogeneous condition in patients with functio-
nal gastrointestinal diseases, but the current know-
ledge does not allow further differentiation of the
subgroups of patients on the basis of symptom phe-
notype(113).
Besides, VH has been sometimes documented
along the entire GI tract in FGIDs patients (33%),
but in general patients with FD have gastric but no
rectal hypersensitivity and IBS patients have rectal
but not gastric hypersensitivity. In about one third
of patients is associated a somatic hypersensitivity
and in this condition probably depends on the fact
that the modulation of a peripheral signal take place
at level of spinal cord or in the brain(113).
In humans pain and discomfort are conscious
experiences which result from a cerebral elaboration
of the visceral afferent signals which are influenced
by cognitive, emotional, motivational factors as well
as memories and by the particular contest.
Conscious perceptions of some changes at gut
level, when arrived in the brain, are filtered, modu-
lated and elaborated in light of previous experien-
ces. Symptom-related anxiety alter the perceptual
responses to pain stimuli via multiple brain mecha-
nisms including descending and opioidergic modu-
lation networks(114, 115). Significant clinical experien-
ces have been made to identify brain areas, circuits
and mechanisms interested in the facilitation and
inhibition of the subjective pain experience(114). 
Significative is the role of the emotional con-
text during the central modulation of the pain sti-
muli arriving from the body and the data of literatu-
re stress the importance of attentional processes in
the modulation of sensory informations(116-118).
The third possible explanation for visceral
hypersensitivity is a defective functioning of
descending anti-nociceptive pathways which origi-
nate in the brainstem and inhibit afferent discharge
in spinal pain pathways. In conclusion, in the
cascade mechanisms provoked by visceral stimuli
at the gut level, resulting in peripheral and spinal
sensitization, central sensory modulation is likely a
crucial factor in the pathophysiology of visceral
hypersensitivity in FGIDs patients.
Stress and Psychological Factors
Frequently patients suffering from FGIDs
refer that stress exacerbates their symptoms. The
percentage of patients with symptoms certainly
related to the stress is very limited (11%)(119).
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In some cases the correlation between the con-
sequences of severe stress, like post-traumatic
stress disorder, and the developing of functional
disorders is evident(120). In FGIDs severe chronic life
stress threat derived from divorce, housing difficul-
ties, business failure, mobbing, death and so on, as
well as the prolonged coping associated with the
stressor, have caused the onset(121) and then the persi-
stence of symptoms(122).
Psychological factors and quality of life are
strictly correlated with the severity of gastrointestinal
symptoms in IBS patients and severity of psycholo-
gical problems is clearly related to visceral hyperal-
gesia(123).
The effects of chronic stress on the gut produce
some alterations in mucosal defense against bacterial
aggression and reduce intestinal permeability via a
cholinergic mechanism that requires the presence of
mucosal mast cells(124).
In conclusion bowel symptoms as a conse-
quence of acute stress have been reported in many
patients with FGIDs, but the variance in gastrointe-
stinal symptoms is poorly significant. On the con-
trary, chronic psychological stress and its effect on
visceral sensitivity seem to have an important role.
Conclusions
Functional gastrointestinal diseases have been
characterized by the presence of chronic or recur-
rent symptoms referable to the gastrointestinal tract,
in the absence of currently recognized biochemical
or structural alterations.
Indeed, patients are characterized by a broad
spectrum of gastrointestinal symptoms, frequently
overlapping between them. 
FGIDs are identified only by symptoms, the-
refore various symptom-based classifications have
been proposed and are known as Manning criteria,
Rome I, Rome II, Rome III. FGIDs include, IBS,
functional bloating, functional constipation, func-
tional diarrhea, and unspecified functional bowel
disorders(125).
Although FGIDs have been dismissed by
many clinicians as non-organic problem, recent stu-
dies suggest, for instance in IBS, some organic
components, in particular interesting the complex
interactions between ENS, ANS and CNS.
There is large wave of interest  in the brain-gut
axis and in the relations existing between brain and
gut, between nerves and hormones, between gut
inflammation, ENS and CNS.
Many peptides in the GI tract are present both
in endocrine cell and in nerve fibers, and many pep-
tides are found in both the brain and the GI tract.
Patients with FGIDs do not fit the typical bio-
medical model of disease because FGIDs seem to
address their etiology to some of the component of
nervous system.
The importance of nervous system for gastro-
intestinal functions in health and disease is more and
more emerging, but today we have not a complete
idea of the pathophysiological role of enteric nervous
system, and accurate and affordable technologies for
in vivo studies of physiology are still required.
Despite of the actual limitations of our know-
ledge, the actually used classifications of FGIDs,
which are symptom based, are no longer defensible. 
Considered that symptoms reported are hetero-
geneous, involving different portions of the gut, fre-
quently overlapping and evaluated that extra-GI
symptoms (fibromyalgia, fatigue, urogenital dysfunc-
tion) are very frequent, investigators and clinicians
must remember that “gut may only be an involved
organ in the context of a systemic problem and not
necessarily the site of the primary pathology”(126).
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